scholarly journals RELATIONSHIP BETWEEN HS-CRP AND ACUTE ISCHEMIC STROKE EVENT IN A SAMPLE POPULATION IN RAJASTHAN

2021 ◽  
Vol 5 (7) ◽  
Author(s):  
Rajesh Khoiwal ◽  
Vipin Sisodia ◽  
Somshekhar Sharma
Keyword(s):  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Diagnostic Marker ◽  
Serum Markers ◽  
Case Control ◽  
Sample Population ◽  
Stroke Event ◽  
Subject Pool ◽  
Hs Crp ◽  
And Control

Use of serum markers has been a established practice in medicine. CRP levels have been known to provide a estimate of inflammation. The present study was formulated to ascertain if levels of CRP in acute ischaemic stroke cases can be a prognostic or diagnostic marker for the condition. The study was a prospective case control format and utilized a subject pool of 50 subjects as case and control each. The study observed a significantly elevated level of CRP in cases with an acute ischaemic stroke. The study concluded that use of CRP can be a an effective modality in clinical practice  in managing such cases. Keywords: CRP, Acute Ischaemic Stroke, TOAST

scholarly journals Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case-control study

2017 ◽  
Vol 83 (9) ◽  
pp. 2045-2055
Author(s):  
Wardati Mazlan-Kepli ◽  
Rachael L. Macisaac ◽  
Matthew Walters ◽  
Philip Michael William Bath ◽  
Jesse Dawson ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Antiplatelet Therapy ◽  
Acute Ischaemic Stroke ◽  
Case Control Study ◽  
Case Control ◽  
Nested Case Control ◽  
Control Study

Symmetric dimethylarginine is a marker of detrimental outcome in the acute phase after ischaemic stroke: role of renal function

2011 ◽  
Vol 122 (3) ◽  
pp. 105-111 ◽  
Author(s):  
Nicole Lüneburg ◽  
Rouven-Alexander von Holten ◽  
Rudolf F. Töpper ◽  
Edzard Schwedhelm ◽  
Renke Maas ◽  
...  
Keyword(s):  
Renal Function ◽  
Clinical Outcome ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Plasma Levels ◽  
Recurrent Stroke ◽  
Composite Endpoint ◽  
Adverse Clinical Outcome ◽  
Symmetric Dimethylarginine ◽  
Stroke Event

Methylarginines have been shown to interfere with NO (nitric oxide) formation by inhibiting NOS (NO synthase)–ADMA (asymmetric dimethylarginine) and cellular L-arginine uptake into the cell [ADMA and SDMA (symmetric dimethylarginine)]. In a recent study, elevation of SDMA was related to long-term mortality in patients recruited 30 days after a stroke event. In the present study, we aimed at investigating the association of SDMA and adverse clinical outcome in the early phase (first 30 days) after acute ischaemic stroke. A total of 137 patients were recruited immediately upon admission to the emergency unit with an acute ischaemic stroke. Plasma levels of methylarginines were determined by a validated LC–MS/MS (liquid chromatography–tandem MS) method. Patients were prospectively followed for 30 days. A total of 25 patients (18.2%) experienced the primary composite endpoint [death, recurrent stroke, MI (myocardial infarction) and rehospitalization]. SDMA plasma levels were significantly higher in stroke patients compared with patients without event (0.89±0.80 compared with 0.51±0.24 μmol/l; P<0.001). SDMA levels were significantly correlated with markers of renal function. Kaplan–Meier survival analysis demonstrated that cumulative survival decreased significantly with ascending tertiles of SDMA (P<0.001). Our study provides the first data indicating that SDMA is strongly associated with adverse clinical outcome during the first 30 days after ischaemic stroke. Our results strengthen the prognostic value of renal function in patients with stroke and confirm the hypothesis that SDMA is a promising marker for renal function.

Viral protein R polymorphisms in the pathogenesis of HIV-associated acute ischaemic stroke: a case–control study

2021 ◽  
Author(s):  
Kate McMullen ◽  
Kathleen Bateman ◽  
Alan Stanley ◽  
Marc Combrinck ◽  
Susan Engelbrecht ◽  
...  
Keyword(s):  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
Viral Protein ◽  
Case Control Study ◽  
Case Control ◽  
Viral Protein R ◽  
Control Study

Carotid endarterectomy following thrombolysis for acute ischaemic stroke

VASA ◽  
2017 ◽  
Vol 46 (2) ◽  
pp. 116-120 ◽  
Author(s):  
Naz Ahmed ◽  
Damian Kelleher ◽  
Manmohan Madan ◽  
Sarita Sochart ◽  
George A. Antoniou
Keyword(s):  
Ischaemic Stroke ◽  
Carotid Endarterectomy ◽  
Acute Ischaemic Stroke ◽  
Intravenous Thrombolysis ◽  
Hospital Length ◽  
Hospital Length Of Stay ◽  
Wound Complications ◽  
Cardiac Complications ◽  
High Dependency ◽  
Low Incidence

Abstract. Background: Insufficient evidence exists to support the safety of carotid endarterectomy (CEA) following intravenous thrombolysis (IVT) for acute ischaemic stroke. Our study aimed to report a single-centre experience of patients treated over a five-year period. Patients and methods: Departmental computerised databases were interrogated to identify patients who suffered an ischaemic stroke and subsequently underwent thrombolysis followed by CEA. Mortality and stroke within 30 days of surgery were defined as the primary outcome end points. Results: Over a five-year period, 177 out of a total of 679 carotid endarterectomies (26 %) were performed in patients presenting with acute ischaemic stroke. Twenty-five patients (14 %) received IVT prior to CEA in the form of alteplase. Sixty percent of patients were male with a mean age of 68 years. Sixteen patients (64 %) underwent CEA within 14 days of IVT and the median interval between thrombolysis and CEA was 7.5 days (range, 3–50 days). One female patient died of a further intraoperative stroke within 30 days of surgery, yielding a mortality rate of 4 %. Two patients (8 %) suffered from cardiac complications postoperatively resulting in a short high dependency unit stay. Another two patients (8 %) developed local wound complications, which were managed conservatively without the need for re-operation. The median hospital length of stay was 4.5 days (range, 1–33 days). Conclusions: Our experience indicates that CEA post-thrombolysis has a low incidence of mortality. Further high quality evidence is required before CEA can be routinely recommended following IVT for acute ischaemic stroke.

Sign in / Sign up

Export Citation Format

Share Document